Cencora, Inc. (NYSE:COR) Shares Sold by US Bancorp DE

US Bancorp DE trimmed its position in shares of Cencora, Inc. (NYSE:COR) by 0.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,277 shares of the company’s stock after selling 79 shares during the period. US Bancorp DE’s holdings in Cencora were worth $11,746,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Fisher Asset Management LLC boosted its stake in Cencora by 17.7% during the 4th quarter. Fisher Asset Management LLC now owns 1,091 shares of the company’s stock valued at $245,000 after acquiring an additional 164 shares during the last quarter. SVB Wealth LLC bought a new position in Cencora during the 4th quarter valued at $431,000. Dynasty Wealth Management LLC bought a new position in Cencora during the 4th quarter valued at $1,871,000. QRG Capital Management Inc. boosted its stake in Cencora by 0.6% during the 4th quarter. QRG Capital Management Inc. now owns 20,142 shares of the company’s stock valued at $4,526,000 after acquiring an additional 122 shares during the last quarter. Finally, Heritage Oak Wealth Advisors LLC bought a new position in Cencora during the 4th quarter valued at $295,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on COR. Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Barclays raised their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, UBS Group raised their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Trading Up 0.7 %

Shares of NYSE:COR opened at $255.22 on Tuesday. The company has a market cap of $49.49 billion, a PE ratio of 36.30, a P/E/G ratio of 1.31 and a beta of 0.49. The company’s 50-day moving average price is $242.26 and its 200 day moving average price is $237.98. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.86%. Cencora’s payout ratio is 31.29%.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.80% of the stock is owned by corporate insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.